Axsome Therapeutics, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +2.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.99 | $-0.99 | +0.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.85 | $-1.26 | -48.2% | Miss | |
| Q4 FY25 | $-0.70 | $-0.71 | -1.4% | Miss | Q4 FY25 call |
| Q3 FY25 | $-0.82 | $-0.94 | -14.6% | Miss | |
| Q2 FY25 | not reported | $-0.92 | not reported | not reported | Q2 FY25 call |
| Q1 FY25 | $-1.26 | $-0.80 | +36.5% | Beat | |
| Q4 FY24 | $-0.90 | $-0.96 | -6.7% | Miss | |
| Q3 FY24 | $-1.38 | $-1.34 | +2.9% | Beat | |
| Q2 FY24 | $-1.30 | $-1.24 | +4.6% | Beat | |
| Q1 FY24 | $-1.20 | $-1.09 | +9.2% | Beat | |
| Q4 FY23 | $-1.21 | $-0.73 | +39.7% | Beat | |
| Q3 FY23 | $-1.24 | $-1.32 | -6.5% | Miss |
Back to AXSM overview · AXSM holders · AXSM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.